PRKAA1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL143316	0.71	15/20
SCHEMBL143624	0.70	15/20
SCHEMBL144216	0.68	15/20
SCHEMBL144123	0.67	15/20
SCHEMBL145613	0.78	14/20
SCHEMBL146648	0.75	14/20
SCHEMBL144696	0.70	14/20
SCHEMBL144746	0.69	14/20
SCHEMBL144060	0.68	14/20
SCHEMBL145323	0.68	14/20
SCHEMBL142533	0.68	14/20
SCHEMBL144201	0.68	14/20
SCHEMBL144305	0.68	14/20
SCHEMBL143534	0.67	14/20
SCHEMBL145122	0.67	14/20
SCHEMBL140217	0.66	14/20
SCHEMBL146002	0.65	14/20
SCHEMBL143925	0.65	14/20
SCHEMBL144150	0.64	14/20
SCHEMBL147078	0.64	14/20

Clinical trials — most relevant to PRKAA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
Metformin Induces a Dietary Restriction-like State in Human	PHASE4	UNKNOWN
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	PHASE4	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease	PHASE2	COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease	PHASE2	NOT_YET_RECRUITING
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction	PHASE2	UNKNOWN
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma	PHASE2	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
NASH AMPK Exercise Dosing (AMPED) Trial	nan	RECRUITING
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Influence of Intermittent Hypoxia on Glycemic Control	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKAA1 binder may also engage these)

Protein	Name	Similarity
P54645	—	1.000	P54645 →
Q5EG47	—	1.000	Q5EG47 →
Q5RDH5	—	1.000	Q5RDH5 →
Q5RD00	—	1.000	Q5RD00 →
Q8BRK8	—	1.000	Q8BRK8 →
PRKAA2	5'-AMP-activated protein kinase catalytic subunit alpha-2	1.000	landscape →
Q09137	—	1.000	Q09137 →
Q28948	—	1.000	Q28948 →
Q852Q2	—	0.995	Q852Q2 →
Q8BHI9	—	0.995	Q8BHI9 →
Q62074	—	0.994	Q62074 →
Q90XF2	—	0.994	Q90XF2 →
F1M7Y5	—	0.994	F1M7Y5 →
Q02956	—	0.994	Q02956 →
Q95ZQ4	—	0.993	Q95ZQ4 →
U4PR86	—	0.993	U4PR86 →
Q09136	—	0.993	Q09136 →
O74536	—	0.992	O74536 →
Q9FLZ3	—	0.992	Q9FLZ3 →
Q5R4K9	—	0.992	Q5R4K9 →
O19111	—	0.992	O19111 →
PRKCZ	Protein kinase C zeta type	0.992	landscape →
NIM1K	Serine/threonine-protein kinase NIM1	0.992	landscape →
P06782	—	0.992	P06782 →
P52497	—	0.992	P52497 →
Q19266	—	0.992	Q19266 →
Q6PFQ0	—	0.991	Q6PFQ0 →
A8WUG4	—	0.991	A8WUG4 →
O08875	—	0.991	O08875 →
PRKCI	Protein kinase C iota type	0.991	landscape →